GlassScriptPhysician profile
Jessica J Scanlon
NPI 1689833857
$1,633.86
in general payments reported to CMS, 2019-2025
19 companies · $637 in 2025
The $637 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $16.49 · 2021: $21.27 · 2022: $126 · 2023: $475 · 2024: $191 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $305.83 | 2022-2025 | Skyrizi, Rinvoq, Botox |
| Lilly USA, LLC | $230.12 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $190.47 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $170.96 | 2023-2025 | |
| Galderma Laboratories, L.P. | $152.64 | 2019-2025 | |
| Ucb, INC. | $95.38 | 2025 | Bimzelx |
| Organon LLC | $91.91 | 2025 | Hadlima |
| Pfizer INC. | $66.37 | 2023-2025 | |
| Incyte Corporation | $63.55 | 2023-2025 | Opzelura |
| Janssen Biotech, INC. | $39.65 | 2025 | Tremfya |
| Dermavant Sciences, INC. | $38.63 | 2023 | Vtama |
| Allergan, INC. | $34.19 | 2019 | |
| Sun Pharmaceutical Industries INC. | $30.28 | 2023 | Absorica Ld, Winlevi |
| Amgen INC. | $23.75 | 2023 | Otezla |
| Verrica Pharmaceuticals INC. | $23.32 | 2025 | Ycanth |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $22.72 | 2023 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $22.02 | 2023 | Sotyktu |
| Chiesi USA, INC. | $16.72 | 2025 | Filsuvez |
| Lnhc, INC | $15.35 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Scanlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.